Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability

Ma, 2015, Temporal trends in mortality in the United States, 1969-2013, JAMA, 314, 1731, 10.1001/jama.2015.12319 Cholesterol Treatment Trialists’ (CTT) Collaboration, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis, JAMA, 316, 1289, 10.1001/jama.2016.13985 Grundy, 2018, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 73, e285, 10.1016/j.jacc.2018.11.003 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664 Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174 Arrieta, 2017, Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial, JAMA Cardiol, 2, 1369, 10.1001/jamacardio.2017.3655 Kazi, 2017, Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial, JAMA, 318, 748, 10.1001/jama.2017.9924 Navar, 2017, Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy, JAMA Cardiol, 2, 1217, 10.1001/jamacardio.2017.3451 Hess, 2017, Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing, Circulation, 136, 2210, 10.1161/CIRCULATIONAHA.117.028430 Virani, 2017, Circulation, 135, 2572, 10.1161/CIRCULATIONAHA.117.028503 Virani, 2019, Applicability and cost implications for proprotein convertase subtilisin/kexin type 9 inhibitors based on the ODYSSEY outcomes trial, Circulation, 139, 410, 10.1161/CIRCULATIONAHA.118.034993 Bian, 2010, ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008, J Manag Care Pharm, 16, 671, 10.18553/jmcp.2010.16.9.671 Salami, 2017, National trends in statin use and expenditures in the US adult population from 2002 to 2013, JAMA Cardiol, 2, 56, 10.1001/jamacardio.2016.4700 Salami, 2018, National trends in nonstatin use and expenditures among the US adult population from 2002 to 2013: insights from Medical Expenditure Panel Survey, J Am Heart Assoc, 7, e007132, 10.1161/JAHA.117.007132 Gencer, 2017, Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines after acute coronary syndromes, J Am Heart Assoc, 6, e006537, 10.1161/JAHA.117.006537 Cannon, 2017, Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease, JAMA Cardiol, 2, 959, 10.1001/jamacardio.2017.2289 Navar, 2020, Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors?, Circ Cardiovasc Qual Outcomes, 13, e006019, 10.1161/CIRCOUTCOMES.119.006019 Kaufman, 2019, Application of PCSK9 inhibitors in practice, Circ Res, 124, 32, 10.1161/CIRCRESAHA.118.314191 Fonarow, 2019, Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease, JAMA Cardiol, 4, 691, 10.1001/jamacardio.2019.1647 Robinson, 2019, Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association, J Clin Lipidol, 13, 525, 10.1016/j.jacl.2019.05.005 Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med, 380, 11, 10.1056/NEJMoa1812792 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Lloyd-Jones, 2017, J Am Coll Cardiol, 70, 1785, 10.1016/j.jacc.2017.07.745 Dixon, 2019, Therapeutic inertia in cardiovascular disease prevention: time to move the bar, J Am Coll Cardiol, 74, 1728, 10.1016/j.jacc.2019.08.014 Antman, 1992, A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction, JAMA, 268, 240, 10.1001/jama.1992.03490020088036 Lau, 1992, Cumulative meta-analysis of therapeutic trials for myocardial infarction, N Engl J Med, 327, 248, 10.1056/NEJM199207233270406